Calithera Biosciences presents preclinical CB-708 data at AACR

Calithera Biosciences announced new data for the company’s CD73 inhibitor CB-708. The data will be presented at the American Association for Cancer Research, or AACR. CB-708 is a selective, oral inhibitor of CD73, an enzyme that synthesizes the immunosuppressive agent adenosine and is over-expressed in multiple tumor types. By blocking adenosine production in the tumor, CB-708 is designed to enhance T-cell activation leading to anti-tumor activity. Calithera plans to initiate clinical development of the compound in the second half of 2019. The preclinical data being presented demonstrates that CB-708 is a potent and selective inhibitor of CD73 that has immune-mediated, single agent activity in syngeneic mouse tumor models. In addition, in pre-clinical studies CB-708 is well-tolerated and shows enhanced anti-tumor activity when combined with either an anti-PD-L1 immunotherapy or with chemotherapeutic agents such as oxaliplatin or doxorubicin.
https://thefly.com/landingPageNews.php?id=2887239